Dr. Andrew M. Roecker
Dr. Roecker's area of interest lies in clinical therapeutics, or the treatment of a patient's diseases and/or disorders using both pharmacologic and non-pharmacologic approaches. Dr. Roecker's main interests are in the infectious disease and oncology disciplines, but general therapeutics is imperative to a pharmacist's knowledge base. Evidence-based medicine is crucial to up-to-date clinical therapeutics and allowing for appropriate dissemination of that information allows for an increased presence of pharmacy in the clinical medicine team. Currently serves as Chair of the Department of Pharmacy Practice and the Director of Continuing Education for the College.
Current Course Curriculum:
- Coordination of the Infectious Disease therapeutic module
- Instruction in the Profession of Pharmacy and Professional Pharmacy Skills courses
- Therapeutics of various disease states within the following modules: Chronic and Ambulatory Medicine, Infectious Disease, Oncology/Gastrointestinal, and the Capstone Modules.
- Coordinate and teach the Infectious Disease Module in the Non-traditional Doctor of Pharmacy program
Contingent/consultant pharmacist at Select Specialty Hospital of Columbus, Ohio. This is a long term/acute care hospital.
- PharmD, Ohio Northern University, Ada, Ohio 2000
- Board Certification in Pharmacotherapy - December 2005 through present
- Roecker AM, Allison JC, Kisor DF. Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncology 2006; 2(4): 441-8.
- Pope SD, Roecker AM. Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Exp Opin Pharmacother 2007; 8(9): 1245-61.
- Roecker AM, Pope SD. Dalbavancin: a lipoglycopeptide antibacterial for gram-positive infections. Exp Opin Pharmacother 2008; 9(10): 1745-54.
- Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights: Oncol 2010; 4: 133-41.
- Armstrong H, Suchecki L, Lipperman S, Roberson T, Roecker AM. Whooping cough: a pharmacist’s role in an emerging epidemic. The Pharmacy and Wellness Review 2014; 5(1): 41-4.
- Orlinski H, Loughlin K, Armstrong H, Blum E, Roecker AM. Advances in treatment of chronic hepatitis C virus (HCV) infection. The Pharmacy and Wellness Review 2014; 5(3): 17-21.
- Roecker AM, Martin SJ. Antimicrobial resistance. In Erstad BL, editor. Critical Care Pharmacotherapy. 1st ed: American College of Clinical Pharmacy; 2015: IN REVIEW
Written Continuing Education Programs
Updates in Treating Community-Acquired Infections – Jefferson County Pharmacist Association – St. Clairsville, Ohio – March 30, 2014
Community-Acquired Infections – Utilizing Treatment Guidelines to Evaluate Prescriptions – Ohio Pharmacists Association Annual Meeting 2014 – Columbus, Ohio – Friday April 4, 2014
Advances in ID Drug Development – Resistance and How are We Doing? – Central Ohio Society of Health-Systems Pharmacists Meeting – Columbus, Ohio – Tuesday April 8, 2014
Community-Acquired Infectious Disease Updates for the Pharmacist: 2014 – Cardinal Retail Business Conference 2014 – Washington, D.C. – Friday July 25, 2014
Updates in HIV/AIDS Treatment for the Community Pharmacist: 2014 – Cardinal Retail Business Conference 2014 – Washington, D.C. – Saturday July 26, 2014
- Improving Patient Adherence: Tools for Success – submitted and funded through Ohio PACE for $73,950 May 2011 through April 2012